
|Slideshows|December 6, 2014
Are We Overtreating DCIS?
Author(s)Laura J. Esserman, MD, MBA
With evidence from a number of studies, this presentation delves into the controversy surrounding the treatment, or overtreatment, of ductal carcinoma in situ (DCIS), and discusses whether or not these lesions should indeed be classified as breast cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Improves Disease Control Vs Cabozantinib in Advanced RCC
2
Lymphoma's Revolution: Evens & Rhodes on CLL, CAR-T, and NJ Care
3
Making Nuanced Decisions on CAR-T and Bispecifics in Multiple Myeloma
4
Lenvatinib/Pembrolizumab Shows Promise After IO Progression in GYN Cancers
5



















































